



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Alaa Rahhal
✉ arahhal1@hamad.qa

RECEIVED 20 February 2025

ACCEPTED 24 February 2025

PUBLISHED 05 March 2025

CITATION

Rahhal A, Hamamyh T, Chapra A, Zaza KJ, Najim M, Hemadneh M, Faraj H, Kanjo W, Yasin A, Toba H, Mohammed W, Hamad MK, Al-Tikrety N, Baraa Habib M, Awaisu A, Mahfouz A, Alyafei S, Arabi AR, Patel A and Al-Hijji M (2025) Corrigendum: Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure. *Front. Cardiovasc. Med.* 12:1580343. doi: 10.3389/fcvm.2025.1580343

COPYRIGHT

© 2025 Rahhal, Hamamyh, Chapra, Zaza, Najim, Hemadneh, Faraj, Kanjo, Yasin, Toba, Mohammed, Hamad, Al-Tikrety, Baraa Habib, Awaisu, Mahfouz, Alyafei, Arabi, Patel and Al-Hijji. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure

Alaa Rahhal^{1*}, Tahseen Hamamyh², Ammar Chapra², Khaled J. Zaza³, Mostafa Najim⁴, Mohammad Hemadneh⁵, Hazem Faraj⁵, Wael Kanjo⁵, Ahmed Yasin⁵, Haneen Toba⁵, Wafa Mohammed⁵, Mohammad Khair Hamad⁶, Nawras Al-Tikrety⁵, Mhd Baraa Habib², Ahmed Awaisu⁷, Ahmed Mahfouz¹, Sumaya Alyafei¹, Abdul Rahman Arabi⁸, Ashfaq Patel⁹ and Mohammed Al-Hijji^{8,10}

¹Pharmacy Department, Hamad Medical Corporation, Doha, Qatar, ²Cardiology Department, Hamad Medical Corporation, Doha, Qatar, ³Anesthesiology, Intensive Care and Perioperative Medicine Department, Hamad Medical Corporation, Doha, Qatar, ⁴Internal Medicine Department, Rochester Regional Health, New York, NY, United States, ⁵Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar, ⁶Endocrinology Department, Hamad Medical Corporation, Doha, Qatar, ⁷Department of Clinical Pharmacy and Practice, Qatar University, Doha, Qatar, ⁸Interventional Cardiology Department, Hamad Medical Corporation, Doha, Qatar, ⁹Heart Failure Department, Hamad Medical Corporation, Doha, Qatar, ¹⁰Department of Medicine, Weill Cornell Medicine, Doha, Qatar

KEYWORDS

acute coronary syndrome, heart failure, sodium–glucose cotransporter-2 (SGLT-2) inhibitors, HF hospitalization, cardioprotection

A Corrigendum on

Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure

By Rahhal A, Hamamyh T, Chapra A, Zaza KJ, Najim M, Hemadneh M, Faraj H, Kanjo W, Yasin A, Toba H, Mohammed W, Hamad MK, Al-Tikrety N, Baraa Habib M, Awaisu A, Mahfouz A, Alyafei S, Arabi A, Patel A and Al-Hijji M. (2024) *Front Cardiovasc Med.* 11. doi: 10.3389/fcvm.2024.1383669

In the published article, there was an error in the Funding statement. The authors declared receiving no financial support for the research, authorship, or publication of this article. The correct Funding statement appears below.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. The Medical Research Center at Hamad Medical Corporation provided the publication open-access fees.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.